RecruitingPhase 2NCT07312188
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
A Phase II Study of F182112 Combined With Different Administration Regimens in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor
Shandong New Time Pharmaceutical Co., LTD
Enrollment
90 participants
Start Date
Jul 2, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma.
Eligibility
Min Age: 18 Years
Inclusion Criteria8
- Be diagnosed with multiple myeloma according to the IMWG 2016 criteria.
- The previous treatment regimen must contain lenalidomide (lenalidomide must be used continuously for at least 2 cycles) and a proteasome inhibitor.
- Participants whose previous treatment regimen contained pomalidomide or who were intolerant to pomalidomide cannot be enrolled.
- Have an ECOG performance status score of 0 - 2.
- Meet at least one of the following measurable disease indicators:
- Serum M - protein ≥ 5 g/L.
- Urine M - protein ≥ 200 mg/24 h.
- Serum free light chain (FLC) test: Involved FLC level ≥ 100 mg/L and abnormal serum free light chain ratio (\< 0.26 or \> 1.65).
Exclusion Criteria5
- Patients with primary light - chain amyloidosis or plasma cell leukemia .
- Patients with symptoms of central nervous system involvement of multiple myeloma.
- Patients with a history of other malignancies other than multiple myeloma within 3 years before the first dose.
- Patients with active mucosal or visceral bleeding.
- Patients who have previously received BCMA - targeted therapy.
Interventions
DRUGF182112+P
F182112 + P
DRUGF182112+CD38
F182112+CD38
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07312188
Related Trials
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
NCT0660471515 locations
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
NCT0565233529 locations
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085266 locations
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
NCT0592757114 locations
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
NCT0637504411 locations